🔎 Trials Near Me

Utama › Penyakit Arteri Koronari › West Virginia

Kajian klinikal Penyakit Arteri Koronari di West Virginia

7 kajian untuk Penyakit Arteri Koronari sedang mencari peserta di lokasi di West Virginia.

Bandar di West Virginia

Teks kajian rasmi (Bahasa Inggeris)

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  • Nephrology and Hypertension Associates, Bluefield
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05485961

Product Surveillance Registry

  • Morgantown
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Sep 2026 · NCT01524276

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

  • Charleston Area Medical Center, Charleston
Mengambil peserta
Umur 18 hingga 80 · Semua jantina · Dikemas kini 31 Ogo 2026 · NCT07258290

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

  • Charleston Area Medical Center, Charleston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06779630

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

  • Huntington VA Medical Center, Huntington, WV, Huntington
Mengambil pesertaFasa 4
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Dis 2025 · NCT02915198

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

  • West Virginia University Heart & Vascular Institute, Morgantown
Mengambil peserta
Umur 18 hingga 80 · Semua jantina · Dikemas kini 11 Sep 2025 · NCT06271590

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

  • West Virginia University and Vascular Institute, Morgantown
Mengambil peserta
Umur 18 hingga 110 · Semua jantina · Dikemas kini 25 Feb 2025 · NCT05908331

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.